Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Becton, Dickinson heads into November earnings with an unusual split: short sellers have been reducing exposure at pace, while the Street's freshest voice just arrived with a bearish initiation.
Barclays kicked off coverage on Wednesday with an Underweight rating and a $165 target, placing it well below the current price of $180.30 and even further below the consensus mean of $194. That initiation is the most newsworthy development of the week. It arrives after a broadly constructive post-earnings reaction in August, when several houses raised targets: B of A Securities lifted to $200, Citigroup to $204, and RBC to $190, all while holding neutral-to-positive ratings. The overall consensus has a sell tilt, but the target distribution tells a more nuanced story: most firms see a higher stock from here, even if few are actively pounding the table. The Barclays $165 target stands out as the only number below the current price among recent actions.
Short positioning offers a counterintuitive backdrop to that fresh bearish call. Short interest has fallen roughly 12% over the past week, dropping to around 3% of the free float, a meaningful retreat from the 4% range seen in mid-September. The direction of travel is clear and consistent: shorts have been unwinding since the mid-month peak, and the borrow market reflects no pressure in either direction. Availability is extremely loose at 1,835%, meaning there are nearly nineteen shares available to borrow for every one currently lent out. That is well above the 52-week tightest reading of 613%, indicating the lending pool has expanded substantially. Cost to borrow has edged up 14% on the week to 0.45%, but that is still a negligible rate for any borrower with conviction. The ORTEX short score has drifted lower across the past two weeks, from around 41.9 to 38.8, consistent with short sellers stepping back rather than pressing.
Options positioning adds a mild defensive note, though not an alarming one. The put/call ratio has edged above its 20-day average to 0.53, roughly one standard deviation above the mean of 0.50. That is a modest shift toward hedging and far from the 52-week high of 0.93. It reads more like routine caution ahead of a November 5 earnings date than any urgent repositioning. The stock is down about 1% on the week and 2.4% over the past month, sitting at $180.30.
On the fundamental side, the bull and bear cases are both anchored in the same story: the pending separation of Biosciences and Diagnostics. Bulls point to a post-deal portfolio spanning a $70 billion total addressable market, with more than 60% of revenue in the United States, high consumables exposure, and a cost discipline programme generating around 8% plant productivity gains. The most recent quarter showed $4.98 billion in revenue with all four segments beating expectations and adjusted EPS of $3.23. Bears counter that the separation still carries execution risk, that FY27 growth guidance is only low-single-digit, and that a roughly 200 basis-point Alaris remediation drag in Q4 offsets much of the margin progress. Factor scores reflect the tug: EPS momentum over 30 days ranks in the 91st percentile and the 12-month forward EPS growth score is 90, but EPS surprise ranks in the 22nd percentile and the EV/EBIT valuation score sits at 36, suggesting the market is not yet rewarding the growth optically on offer.
Institutional flows are stable rather than directional. BlackRock holds 9% of shares and added modestly in the most recent period. State Street added 1.18 million shares. First Eagle crossed the 5% threshold in August and filed a fresh Schedule 13G, a passive disclosure with no activist intent. No Schedule 13D has been filed, and no activist is on the register. The Vanguard Group's original 13G filing went to zero in March, replaced by two separate Vanguard entities holding 7.5% and 5.4% respectively, a structural reorganisation rather than an exit. Insider activity over the past 90 days shows a net sale of just under 7,000 shares, dominated by small pre-arranged 10b5-1 plan sales from the Chief Revenue Officer and a CEO option exercise with an associated tax-related sale in August. Nothing in the insider register reads as a conviction trade.
The next earnings print on November 5 is the natural focal point. The most recent comparable release in August produced a 3.6% one-day gain and a 6.6% five-day move higher. Whether the market reacts similarly will depend on how much execution progress the company can demonstrate on the separation, and whether the Alaris drag materialises at the guided level.
See the live data behind this article on ORTEX.
Open BDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
